A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene

We describe a Sanger sequencing protocol for SARS‐CoV‐2 S‐gene the Spike (S)‐glycoprotein product of which, composed of receptor‐binding (S1) and membrane fusion (S2) segments, is the target of vaccines used to combat COVID‐19. The protocol can be used in laboratories with basic Sanger sequencing ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Rodney S., Harvey, Ruth, Ermetal, Burcu, Xiang, Zheng, Galiano, Monica, Adams, Lorin, McCauley, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447197/
https://www.ncbi.nlm.nih.gov/pubmed/34346163
http://dx.doi.org/10.1111/irv.12892
_version_ 1784569010168266752
author Daniels, Rodney S.
Harvey, Ruth
Ermetal, Burcu
Xiang, Zheng
Galiano, Monica
Adams, Lorin
McCauley, John W.
author_facet Daniels, Rodney S.
Harvey, Ruth
Ermetal, Burcu
Xiang, Zheng
Galiano, Monica
Adams, Lorin
McCauley, John W.
author_sort Daniels, Rodney S.
collection PubMed
description We describe a Sanger sequencing protocol for SARS‐CoV‐2 S‐gene the Spike (S)‐glycoprotein product of which, composed of receptor‐binding (S1) and membrane fusion (S2) segments, is the target of vaccines used to combat COVID‐19. The protocol can be used in laboratories with basic Sanger sequencing capabilities and allows rapid “at source” screening for SARS‐CoV‐2 variants, notably those of concern. The protocol has been applied for surveillance, with clinical specimens collected in either nucleic acid preservation lysis‐mix or virus transport medium, and research involving cultured viruses, and can yield data of public health importance in a timely manner.
format Online
Article
Text
id pubmed-8447197
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84471972021-09-17 A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene Daniels, Rodney S. Harvey, Ruth Ermetal, Burcu Xiang, Zheng Galiano, Monica Adams, Lorin McCauley, John W. Influenza Other Respir Viruses Short Communications We describe a Sanger sequencing protocol for SARS‐CoV‐2 S‐gene the Spike (S)‐glycoprotein product of which, composed of receptor‐binding (S1) and membrane fusion (S2) segments, is the target of vaccines used to combat COVID‐19. The protocol can be used in laboratories with basic Sanger sequencing capabilities and allows rapid “at source” screening for SARS‐CoV‐2 variants, notably those of concern. The protocol has been applied for surveillance, with clinical specimens collected in either nucleic acid preservation lysis‐mix or virus transport medium, and research involving cultured viruses, and can yield data of public health importance in a timely manner. John Wiley and Sons Inc. 2021-08-03 2021-11 /pmc/articles/PMC8447197/ /pubmed/34346163 http://dx.doi.org/10.1111/irv.12892 Text en © 2021 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communications
Daniels, Rodney S.
Harvey, Ruth
Ermetal, Burcu
Xiang, Zheng
Galiano, Monica
Adams, Lorin
McCauley, John W.
A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
title A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
title_full A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
title_fullStr A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
title_full_unstemmed A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
title_short A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene
title_sort sanger sequencing protocol for sars‐cov‐2 s‐gene
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447197/
https://www.ncbi.nlm.nih.gov/pubmed/34346163
http://dx.doi.org/10.1111/irv.12892
work_keys_str_mv AT danielsrodneys asangersequencingprotocolforsarscov2sgene
AT harveyruth asangersequencingprotocolforsarscov2sgene
AT ermetalburcu asangersequencingprotocolforsarscov2sgene
AT xiangzheng asangersequencingprotocolforsarscov2sgene
AT galianomonica asangersequencingprotocolforsarscov2sgene
AT adamslorin asangersequencingprotocolforsarscov2sgene
AT mccauleyjohnw asangersequencingprotocolforsarscov2sgene
AT danielsrodneys sangersequencingprotocolforsarscov2sgene
AT harveyruth sangersequencingprotocolforsarscov2sgene
AT ermetalburcu sangersequencingprotocolforsarscov2sgene
AT xiangzheng sangersequencingprotocolforsarscov2sgene
AT galianomonica sangersequencingprotocolforsarscov2sgene
AT adamslorin sangersequencingprotocolforsarscov2sgene
AT mccauleyjohnw sangersequencingprotocolforsarscov2sgene

Ejemplares similares